{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T04:28:34Z","timestamp":1792988914136,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007921","name":"University of Pittsburgh","doi-asserted-by":"publisher","award":["SCR_022735"],"award-info":[{"award-number":["SCR_022735"]}],"id":[{"id":"10.13039\/100007921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007921","name":"University of Pittsburgh","doi-asserted-by":"publisher","award":["S10OD028483"],"award-info":[{"award-number":["S10OD028483"]}],"id":[{"id":"10.13039\/100007921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01 DK122990"],"award-info":[{"award-number":["R01 DK122990"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01 DK135566"],"award-info":[{"award-number":["R01 DK135566"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10OD028483"],"award-info":[{"award-number":["S10OD028483"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 DK120531"],"award-info":[{"award-number":["P30 DK120531"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001039","name":"Cleveland Foundation","doi-asserted-by":"publisher","award":["P30 DK120531"],"award-info":[{"award-number":["P30 DK120531"]}],"id":[{"id":"10.13039\/100001039","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajp.amjpathol.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ajpath.2026.04.015","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T02:18:21Z","timestamp":1778552301000},"page":"1563-1580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hepatocyte-specific PPAR\u03b3 Deletion Uncovers Role of an Antagonistic PPAR\u03b3\u2013HNF4\u03b1 Transcriptional Axis in Metabolic Dysfunction\u2013Associated Steatotic Liver Disease Progression"],"prefix":"10.1016","volume":"196","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8927-9826","authenticated-orcid":false,"given":"Shehnaz","family":"Bano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9248-5938","authenticated-orcid":false,"given":"Matthew A.","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3677-613X","authenticated-orcid":false,"given":"Jia-Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Orr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2298-3725","authenticated-orcid":false,"given":"John W.","family":"Stoops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy M.","family":"Mars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1840-9520","authenticated-orcid":false,"given":"Silvia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4190-188X","authenticated-orcid":false,"given":"Joseph","family":"Locker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9922-6920","authenticated-orcid":false,"given":"George K.","family":"Michalopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Bhushan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2026.04.015_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2026.04.015_bib2","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ajpath.2026.04.015_bib3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/347645a0","article-title":"Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators","volume":"347","author":"Issemann","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2026.04.015_bib4","doi-asserted-by":"crossref","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","article-title":"An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)","volume":"270","author":"Lehmann","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2026.04.015_bib5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2008.03.078","article-title":"Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) trial","volume":"135","author":"Ratziu","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2026.04.015_bib6","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2026.04.015_bib7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajpath.2026.04.015_bib8","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-22-0155","article-title":"Role of hepatic peroxisome proliferator-activated receptor [gamma] in non-alcoholic fatty liver disease","volume":"257","author":"Lee","year":"2023","journal-title":"J Endocrinol"},{"key":"10.1016\/j.ajpath.2026.04.015_bib9","doi-asserted-by":"crossref","first-page":"34268","DOI":"10.1074\/jbc.M300043200","article-title":"Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass","volume":"278","author":"Gavrilova","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2026.04.015_bib10","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.cmet.2008.03.003","article-title":"Hepatic steatosis in leptin-deficient mice is promoted by the PPARgamma target gene Fsp27","volume":"7","author":"Matsusue","year":"2008","journal-title":"Cell Metab"},{"key":"10.1016\/j.ajpath.2026.04.015_bib11","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqab175","article-title":"Rosiglitazone requires hepatocyte PPAR[gamma] expression to promote steatosis in male mice with diet-induced obesity","volume":"162","author":"Lee","year":"2021","journal-title":"Endocrinology"},{"key":"10.1016\/j.ajpath.2026.04.015_bib12","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jhep.2013.06.023","article-title":"Cell-specific PPAR[gamma] deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells","volume":"59","author":"Mor\u00e1n-Salvador","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2026.04.015_bib13","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1172\/JCI118703","article-title":"Regulation of PPAR gamma gene expression by nutrition and obesity in rodents","volume":"97","author":"Vidal-Puig","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajpath.2026.04.015_bib14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/JOE-16-0447","article-title":"Hepatocyte-specific, PPAR[gamma]-regulated mechanisms to promote steatosis in adult mice","volume":"232","author":"Wolf Greenstein","year":"2017","journal-title":"J Endocrinol"},{"key":"10.1016\/j.ajpath.2026.04.015_bib15","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1172\/JCI200317223","article-title":"Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes","volume":"111","author":"Matsusue","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajpath.2026.04.015_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/hep.510310117","article-title":"Peroxisome proliferator-activated receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells","volume":"31","author":"Galli","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2026.04.015_bib17","article-title":"Effect of modulation of PPAR-[gamma] activity on Kupffer cells M1\/M2 polarization in the development of non-alcoholic fatty liver disease","volume":"7","author":"Luo","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajpath.2026.04.015_bib18","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1038\/s41467-020-16092-0","article-title":"Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis","volume":"11","author":"An","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2026.04.015_bib19","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.jcmgh.2021.01.003","article-title":"Hepatocyte-specific loss of PPAR[gamma] protects mice from NASH and increases the therapeutic effects of rosiglitazone in the liver","volume":"11","author":"Lee","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2026.04.015_bib20","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/hep.30696","article-title":"Pharmacologic inhibition of epidermal growth factor receptor suppresses nonalcoholic fatty liver disease in a murine fast-food diet model","volume":"70","author":"Bhushan","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2026.04.015_bib21","doi-asserted-by":"crossref","first-page":"G825","DOI":"10.1152\/ajpgi.00145.2011","article-title":"Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition","volume":"301","author":"Charlton","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.ajpath.2026.04.015_bib22","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ajpath.2025.09.010","article-title":"Hepatocyte-specific MET deletion exacerbates acetaminophen-induced hepatotoxicity in mice","volume":"196","author":"Jain","year":"2026","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajpath.2026.04.015_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/toxsci\/kfaf151","article-title":"Hepatocyte-specific epidermal growth factor receptor (EGFR) deletion attenuates acetaminophen-induced liver injury in mice","volume":"209","author":"Jain","year":"2026","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.ajpath.2026.04.015_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcmgh.2024.101380","article-title":"Hepatocyte-specific epidermal growth factor receptor deletion promotes fibrosis but has no effect on steatosis in fast-food diet model of metabolic dysfunction-associated steatotic liver disease","volume":"18","author":"Bano","year":"2024","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2026.04.015_bib25","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/MCB.06175-11","article-title":"Genome-wide profiling of liver X receptor, retinoid X receptor, and peroxisome proliferator-activated receptor [alpha] in mouse liver reveals extensive sharing of binding sites","volume":"32","author":"Boergesen","year":"2012","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ajpath.2026.04.015_bib26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.isci.2018.10.018","article-title":"Binding of drug-activated CAR\/Nr1i3 alters metabolic regulation in the liver","volume":"9","author":"Tian","year":"2018","journal-title":"iScience"},{"key":"10.1016\/j.ajpath.2026.04.015_bib27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0960-0760(97)00182-9","article-title":"The peroxisome proliferator-activated receptors at the cross-road of diet and hormonal signalling","volume":"65","author":"Desvergne","year":"1998","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.ajpath.2026.04.015_bib28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev.biochem.77.061307.091829","article-title":"Fat and beyond: the diverse biology of PPARgamma","volume":"77","author":"Tontonoz","year":"2008","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.ajpath.2026.04.015_bib29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrendo.2016.135","article-title":"PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD","volume":"13","author":"Gross","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ajpath.2026.04.015_bib30","doi-asserted-by":"crossref","first-page":"11392","DOI":"10.1074\/jbc.M310284200","article-title":"Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells","volume":"279","author":"Hazra","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2026.04.015_bib31","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1053\/gast.2002.33666","article-title":"Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro","volume":"122","author":"Galli","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2026.04.015_bib32","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jcmgh.2023.11.009","article-title":"Mechanism and effect of HNF4[alpha] decrease in a rat model of cirrhosis and liver failure","volume":"17","author":"Melis","year":"2024","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2026.04.015_bib33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00018-022-04629-z","article-title":"Hepatocyte PPAR[gamma] contributes to the progression of non-alcoholic steatohepatitis in male and female obese mice","volume":"80","author":"Lee","year":"2023","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.ajpath.2026.04.015_bib34","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/hep.32326","article-title":"Progressive loss of hepatocyte nuclear factor 4 alpha activity in chronic liver diseases in humans","volume":"76","author":"Gunewardena","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2026.04.015_bib35","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/hep.31604","article-title":"Hepatocyte nuclear factor 4[alpha] prevents the steatosis-to-NASH progression by regulating p53 and bile acid signaling (in mice)","volume":"73","author":"Xu","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2026.04.015_bib36","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1097\/CM9.0000000000002092","article-title":"Hepatocyte nuclear factor 4[alpha] in the pathogenesis of non-alcoholic fatty liver disease","volume":"135","author":"Pan","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.ajpath.2026.04.015_bib37","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jhep.2021.08.011","article-title":"Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model","volume":"75","author":"Yang","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2026.04.015_bib38","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2337\/db10-0705","article-title":"Differential lipid partitioning between adipocytes and tissue macrophages modulates macrophage lipotoxicity and M2\/M1 polarization in obese mice","volume":"60","author":"Prieur","year":"2011","journal-title":"Diabetes"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944026001379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944026001379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:25:56Z","timestamp":1789604756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944026001379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0002944026001379"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2026.04.015","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatocyte-specific PPAR\u03b3 Deletion Uncovers Role of an Antagonistic PPAR\u03b3\u2013HNF4\u03b1 Transcriptional Axis in Metabolic Dysfunction\u2013Associated Steatotic Liver Disease Progression","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2026.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Society for Investigative Pathology.","name":"copyright","label":"Copyright"}]}}